TY  - JOUR
AU  - Menzer, Christian
AU  - Menzies, Alexander M
AU  - Carlino, Matteo S
AU  - Reijers, Irene
AU  - Groen, Emma J
AU  - Eigentler, Thomas
AU  - de Groot, Jan Willem B
AU  - van der Veldt, Astrid A M
AU  - Johnson, Douglas B
AU  - Meiss, Frank
AU  - Schlaak, Max
AU  - Schilling, Bastian
AU  - Westgeest, Hans M
AU  - Gutzmer, Ralf
AU  - Pföhler, Claudia
AU  - Meier, Friedegund
AU  - Zimmer, Lisa
AU  - Suijkerbuijk, Karijn P M
AU  - Haalck, Thomas
AU  - Thoms, Kai-Martin
AU  - Herbschleb, Karin
AU  - Leichsenring, Jonas
AU  - Menzer, Alexander
AU  - Kopp-Schneider, Annette
AU  - Long, Georgina V
AU  - Kefford, Richard
AU  - Enk, Alexander
AU  - Blank, Christian U
AU  - Hassel, Jessica C
TI  - Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
JO  - Journal of clinical oncology
VL  - 37
IS  - 33
SN  - 1527-7755
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2019-02337
SP  - 3142-3151
PY  - 2019
N1  - 37(33):3142-3151
AB  - BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K-mutated metastatic melanoma. For patients with less frequent BRAF mutations, however, efficacy data are limited.In the current study, 103 patients with metastatic melanoma with rare, activating non-V600E/K BRAF mutations that were treated with either a BRAF inhibitor (BRAFi), MEK inhibitor (MEKi), or the combination were included. BRAF mutation, patient and disease characteristics, response, and survival data were analyzed.Fifty-eight patient tumors (56
LB  - PUB:(DE-HGF)16
C6  - pmid:31580757
DO  - DOI:10.1200/JCO.19.00489
UR  - https://inrepo02.dkfz.de/record/147211
ER  -